Anupam Rasayan India Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹806 Cr +10.3% YoYSee revenue, profit and what management said. You are viewing Q3 FY26.
AR

Anupam Rasayan India Ltd

Q3 FY26Chemicals & Petrochemicals

Anupam Rasayan India Q3 FY26 earnings call: Revenue & Margins

Q3 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹512Cr
+31.3% YoY
−30% QoQ
Net profit
₹61Cr
+13% YoY
+7% QoQ
Margin
25%
−7 pp YoY
+6 pp QoQ
Price₹1,244
Market cap₹13.8K Cr
P/E81.4

The short version

Q3 9MFY26 revenue grew 84% YoY to INR 1,730 crores, indicating strong growth momentum. Anupam Rasayan expects continued growth momentum into FY27, supported by a strong pipeline, deeper customer relationships, and expanding global footprints.

From Anupam Rasayan India Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Q3 9MFY26 revenue grew 84% YoY to INR 1,730 crores, indicating strong growth momentum.
  • Management optimistic about continuing growth into FY27, driven by robust pipeline and deepening global customer relationships.
  • Expansion supported by scaling up commercial molecules and ramping up capacity utilization.
  • Focus on ramping up Pharma and Performance Material portfolios, which showed significant growth (Pharma up 85%, Performance Materials up 245% YoY for 9MFY26).
  • Pipeline includes 65+ molecules in R&D/pilot stages, supporting future revenue growth.
  • Acquisition of Jayhawk Fine Chemicals to strengthen North America footprint, expanding access to innovation-driven sectors (semiconductors, automotive, pharma, EV).

2 more points from Anupam Rasayan India Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Anupam Rasayan India Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • It highlights the strategic acquisition of Jayhawk Fine Chemicals, a US-based specialty chemicals company, expected to close soon, which represents a significant capital investment expanding Anupam's footprint in the US.
  • This acquisition strengthens supply chain presence, technology, customer base, and product portfolio across high-value sectors like semiconductors, pharma, EV, and aerospace.
  • The company also focuses on ramping up capacity utilization across manufacturing assets and smoothly integrating Jayhawk, implying ongoing investments in operational expansion.
  • The management emphasizes growth driven by expanding global footprints, pipeline commercialization, and technology enhancement, indicating possible capex aligned with these goals going forward.

Top-ranked in Chemicals & Petrochemicals

Ranked on what management guided this quarter

Guidance-ranked
2Shiv Texchem
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Anupam Rasayan India Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • In 9MFY26, Letters of Intent (LOIs) and contracts contributed over INR 250 crores of revenue, indicating strong conversion of the order pipeline into commercial revenue.
  • The company has a robust pipeline with over 65 molecules across R&D and pilot stages in Pharma and Polymer segments.
  • The Pharma segment has more than 30 molecules under development and pilot stages.

2 more points from Anupam Rasayan India Ltd's call on order book

Create a free account to keep reading this call

Anupam Rasayan India Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Anupam Rasayan India Ltd Q3 FY26 results — key figures

Anupam Rasayan India Ltd Q3 FY26 reported results vs Q3 FY25, ₹ crore
₹ CrQ3 FY26Q3 FY25YoYQ2 FY26QoQ
Revenue512390+31.3%731-30%
Operating profit (EBITDA)127124+2.4%136-6.6%
Operating margin25%32%-7 pp19%+6 pp
Profit before tax6059+1.7%76-21.1%
Net profit (PAT)6154+13%57+7%
EPS (₹)4.312.56+68.4%3.90+10.5%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹806 Cr, net profit ₹65 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Chemicals & Petrochemicals this season

  • Neochem Bio (Q3 FY26)

    Revenue for Q2 FY26 (Sept’25) stood at ₹4,583.16 Lakh. Key investor presentation takeaways from Neochem Bio Solutions Ltd's Q3 FY26 investor presentation — and

  • Thirumalai Chemicals (Q3 FY26)

    Q3 FY26 Revenue from Operations (INR Cr):** . Key investor presentation takeaways from Thirumalai Chemicals Ltd's Q3 FY26 investor presentation — and how it ran

  • IVP (Q3 FY26)

    Q3 FY26 Revenue from Operations: ₹144.97 crore . Key investor presentation takeaways from IVP's Q3 FY26 investor presentation — and how it ranks against sector

  • Gujarat Alkalies (Q3 FY26)

    3,144.48 Crores, down from Rs. Key investor presentation takeaways from Gujarat Alkalies & Chemicals Ltd's Q3 FY26 investor presentation — and how it ranks agai

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Anupam Rasayan India Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Anupam Rasayan India Ltd Q3 FY26 results?

Q3 9MFY26 revenue grew 84% YoY to INR 1,730 crores, indicating strong growth momentum. Anupam Rasayan expects continued growth momentum into FY27, supported by a strong pipeline, deeper customer relationships, and expanding global footprints.

What is Anupam Rasayan India Ltd share price analysis?

Anupam Rasayan India Ltd currently shows a neutral. The stock trades at a P/E of 81.4 with a market cap of ₹13,847 Cr. Investors should review the full earnings analysis for detailed insights.

Keep Anupam Rasayan India Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.